Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280681 | 0.88 | OPRM1 (0.79) | OPRM1OPRK1OPRL1OPRD1MEN1 | |
| SCHEMBL14280684 | 0.75 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1MEN1 | |
| SCHEMBL5423746 | 0.73 | OPRM1 (0.57) | OPRM1OPRK1OPRL1OPRD1MEN1 | |
| SCHEMBL18474336 | 0.72 | OPRM1 (0.71) | OPRM1OPRK1OPRL1OPRD1MEN1 | |
| SCHEMBL14280677 | 0.72 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL11035627 | 0.72 | OPRM1 (0.62) | OPRM1OPRK1OPRL1OPRD1MEN1 | |
| SCHEMBL4766493 | 0.71 | OPRM1 (0.59) | OPRM1OPRK1OPRL1OPRD1HTR2A | |
| SCHEMBL2817646 | 0.71 | OPRM1 (0.55) | OPRM1OPRK1OPRL1ACHEMEN1 | |
| SCHEMBL5427649 | 0.70 | KMT2A (0.55) | OPRM1OPRK1OPRL1OPRD1ACHE | |
| SCHEMBL1388824 | 0.69 | DRD2 (0.54) | OPRM1OPRK1OPRL1ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRK1 5/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.